F-star Therapeutics Stock Jumps On Licensing Pact For STING Inhibitors With AstraZeneca

  • F-star Therapeutics Inc FSTX has entered into an exclusive licensing agreement with AstraZeneca plc AZN for research, development, and commercialization of next-generation Stimulator of Interferon Genes (STING) inhibitor compounds.
  • Under the terms of the agreement, AstraZeneca is granted exclusive access to F-star's novel preclinical STING inhibitors. 
  • AstraZeneca will be responsible for all future R&D and commercialization of the STING inhibitor compounds.
  • F-star will retain rights to all STING agonists currently in clinical development for cancer.
  • F-star is eligible to receive upfront and near-term payments of up to $12 million and milestone payments of over $300 million, as well as royalty payments. 
  • Price Action: FSTX shares are up 15.4% at $8.47, and AZN shares are down 0.97% at $59.18 during the premarket session on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareContractsGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!